Evolution of the Average Target: Incyte Corporation

Evolution of the Target Price: Incyte Corporation

Changes in Analyst Recommendations: Incyte Corporation

7e0d0d11a57df4.baBwjFrTLrHIMuJMdDTJyoU8vbLUlbqM6wlwQVSewGk.J5Ux1S_rHeWFbYYoFWH7m9Fu3_SEzNj-rVsxNxzmsAYbxjHTEppb960Bpw~3fd73209943f78e01a88279d6c3d2f92
07-15 BofA Securities Raises Incyte Price Target to $136 From $124 MT
07-14 Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating MT
07-13 Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says MT
07-13 BMO Capital Adjusts Price Target on Incyte to $112 From $94, Maintains Market Perform Rating MT
07-13 Jefferies Adjusts Price Target on Incyte to $105 From $100, Maintains Hold Rating MT
07-07 RBC Capital Adjusts Incyte Price Target to $99 From $95, Maintains Sector Perform Rating MT
06-26 UBS Adjusts Price Target on Incyte to $113 From $103, Maintains Neutral Rating MT
06-25 UBS Adjusts Price Target on Incyte to $113 From $103 MT
06-22 Truist Securities Raises Incyte Price Target to $105 From $103, Hold Rating Kept MT
06-22 Analyst recommendations: Accenture, Conocophillips, Diamondback Energy, Oracle, Applied Materials… Zonebourse
06-22 BMO Capital Upgrades Incyte to Market Perform From Underperform, Adjusts PT to $94 From $75 MT
06-18 Jefferies Raises Incyte Price Target to $100 From $94, Maintains Hold Rating MT
06-11 Guggenheim Lifts Price Target on Incyte to $136 From $130, Maintains Buy Rating MT
06-11 William O'Neil Initiates Incyte at Buy MT
06-11 Analyst recommendations: Chewy, CME Group, Ford Motor, Fortinet, Humana… Zonebourse
06-09 HC Wainwright Adjusts Incyte Price Target to $140 From $135, Maintains Buy Rating MT
06-08 Oppenheimer Adjusts Price Target on Incyte to $107 From $90, Maintains Perform Rating MT
05-22 Bernstein Initiates Incyte at Market Perform With $99 Price Target MT
04-29 Leerink Partners Adjusts Incyte Price Target to $131 From $129, Maintains Outperform Rating MT
04-29 Morgan Stanley Adjusts Incyte Price Target to $103 From $102, Maintains Equal Weight Rating MT
04-29 TD Cowen Adjusts Incyte Price Target to $124 From $123, Maintains Buy Rating MT
04-29 Stifel Nicolaus Adjusts Incyte Price Target to $123 From $120, Maintains Buy Rating MT
04-29 Oppenheimer Adjusts Price Target on Incyte to $90 From $84, Maintains Perform Rating MT
04-28 TD Cowen Raises Incyte Price Target to $124 From $123 MT
04-28 Morgan Stanley Adjusts Price Target on Incyte to $102 From $94, Maintains Equalweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-2.43%
+20.88%
+21.14%
+47%
+13.19%
+7.91%
-23.57%
+24.72%
+4.66%
+31.01%
Average +14.45%
Weighted average by Cap. +17.18%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
116.65USD
Average target price
113.82USD
Spread / Average Target
-2.43%
High Price Target
140.00USD
Spread / Highest target
+20.02%
Low Price Target
71.00USD
Spread / Lowest Target
-39.13%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
Barclays
BMO Capital
Jefferies & Co.
RBC Capital Markets
UBS
Truist Securities
Guggenheim
William O'Neil & Co
HC Wainwright
Oppenheimer
Bernstein
Leerink Partners
Morgan Stanley
TD Cowen
Stifel Nicolaus
Goldman Sachs
Evercore ISI
Argus
Deutsche Bank Securities
Wells Fargo Securities
Piper Sandler
Mizuho Securities
JPMorgan Chase
Wolfe Research
Citigroup
William Blair & Co.
JMP Securities
SVB Securities LLC
Morningstar
Cowen
SVB Leerink
Benchmark Capital
Credit Suisse
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
116.65USD
Average target price
113.82USD
Spread / Average Target
-2.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock
  4. Consensus Incyte Corporation